Pioneering Research to Develop Safe & Effective Immunomodulators to Stimulate the Soluble Tumor Microenvironment
Therapeutically targeting of soluble immune modulators in the tumor microenvironment (TME) has been shown to create ‘hot’ tumors, increasing T cell infiltration and better response rates to immune checkpoint blockade treatment.
As the whole immuno-oncology research community now pivots to engineering soluble factors and cytokines to transform the TME into an immunostimulatory state, acting as a complementary strategy to a suite of cancer immunotherapy approaches, the virtual Cytokine-Based Cancer Immunotherapies Summit has been established.
This is the ONLY industry dedicated meeting dedicated specifically to cytokine therapies. Join this exclusive community online to network and learn from the leading experts in pharma, biotech and academia, as we discuss how to successfully and safely deliver cytokine therapies to a plethora of cancer indications.
With 2 content packed digital days covering the latest results coming out of the clinic and addressing the shortfalls of these therapies, this is not one to miss!
World-Class Speaker Faculty Includes:
Chief Scientific Officer
Head Oncology Programs, Department Head Cancer Immunotherapy Discovery 3
Roche Pharma Research & Early Development
Co-CEO and CSO, Professor
Philogen & ETH Zürich
Staff Clinician, Developmental Therapeutics Clinic
National Cancer Institute
Director - Tumor Microenvironment Translational Biomarkers
Bristol-Myers Squibb Co.